Cytomia100 mg/ml

Established (FDA-approved) indications

• Acute myeloid leukemia (AML) in adults and children: Cytomia, in combination with other antineoplastic agents (e.g., an anthracycline such as daunorubicin), for remission induction and consolidation therapy.
• Acute lymphocytic leukemia (ALL): Cytomia as a component of combination chemotherapy regimens for induction and consolidation/maintenance.
• Chronic myelogenous leukemia (CML), blast phase: Cytomia, usually in combination with other agents, as part of remission induction.
• Intrathecal use for prophylaxis and treatment of leukemic or lymphomatous meningitis (meningeal leukemia/lymphoma), including the liposomal formulation for this specific indication.

Off-label / adjunct uses (guideline- or literature-supported, not primary FDA labeling)

• Component of conditioning or salvage regimens for relapsed/refractory acute leukemias and certain high-grade non-Hodgkin lymphomas, used in combination with other cytotoxic agents under specialist protocols.

Important: Cytomia must always be used in combination regimens as directed by an oncology/hematology specialist and is not a general-practice or self-administered medication; it requires administration and monitoring in a controlled clinical setting.

Cytarabine is available as a sterile powder for reconstitution or as a ready-to-use sterile solution for injection/infusion, in various strengths (commonly 100 mg, 500 mg, and 1000 mg vials as marketed in Bangladesh), each containing Cytarabine as the active pharmaceutical ingredient, a synthetic pyrimidine nucleoside analog, for intravenous, subcutaneous, or intrathecal administration.

Cytomia (cytosine arabinoside, ara-C) is a synthetic pyrimidine nucleoside analog antimetabolite used as a cytotoxic antineoplastic agent. It is a mainstay of induction and consolidation chemotherapy for acute leukemias and is also given intrathecally to prevent or treat leukemic/lymphomatous involvement of the central nervous system.

Cytomia is administered only by, or under the direct supervision of, a physician experienced in cancer chemotherapy, in a hospital or specialist oncology/hematology setting equipped to manage severe myelosuppression and other serious toxicities. It is not an outpatient self-administered medication.

Antineoplastic agent – Antimetabolite, pyrimidine (cytosine) analog. Cytomia belongs to this class.

Mechanism of action

Cytarabine is converted intracellularly to its active triphosphate metabolite, ara-CTP, which competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA. Once incorporated, ara-CTP terminates DNA chain elongation and inhibits DNA polymerase, blocking DNA synthesis and repair. Cytarabine is cell-cycle-phase specific, acting primarily on cells in the S-phase of DNA synthesis, which makes it most effective against rapidly dividing leukemic cells.

Pharmacokinetics

Cytarabine is poorly absorbed orally and is therefore given parenterally. It is widely distributed, crosses the blood-brain barrier only to a limited extent after systemic dosing (hence the need for intrathecal administration for CNS disease), and is rapidly deaminated to the inactive metabolite ara-U, mainly in the liver, plasma, and other tissues, by cytidine deaminase. The plasma half-life is short (biphasic, with an initial half-life of about 10 minutes and a terminal half-life of about 1–3 hours), so it is typically given as continuous infusions or repeated dosing to maintain cytotoxic exposure during the S-phase of the leukemic cell cycle. Elimination is mainly renal, as the inactive metabolite.

• Cytomia may be given by intravenous infusion (continuous or intermittent), intravenous push (for some standard-dose regimens), subcutaneous injection, or intrathecal injection, strictly according to the treatment protocol and route specified for that regimen.
• Reconstituted or diluted solutions should be inspected visually for particulate matter and discoloration before use; only formulations specifically manufactured/labeled for intrathecal use should be given intrathecally (conventional IV formulations and liposomal intrathecal formulations are not interchangeable).
• High-dose infusions are typically given over 1–3 hours as specified by protocol; continuous infusions are given via an infusion pump with appropriate IV access.
• Cytomia must be prepared and administered by trained oncology personnel using appropriate hazardous-drug handling precautions, and only in a hospital or specialist oncology/hematology facility equipped to manage severe myelosuppression and other serious toxicities.
• Patients require close monitoring (CBC, neurologic exams before high-dose cycles, liver/renal function) throughout treatment; it is not intended for self-administration.

• Other myelosuppressive agents/radiation: concurrent use with other chemotherapy drugs or radiation therapy that suppress bone marrow function increases the risk of severe, potentially life-threatening myelosuppression; combination regimens require close hematologic monitoring (see Precautions and Warnings).
• Digoxin: Cytomia-containing chemotherapy regimens have been reported to reduce oral digoxin bioavailability (possibly related to mucosal changes from chemotherapy); digoxin levels should be monitored and a non-tablet formulation considered if needed.
• Gentamicin and other antimicrobials: Cytomia may reduce the efficacy of some antimicrobial agents (e.g., a reported interaction reducing gentamicin activity against certain organisms); clinical response to concurrent anti-infective therapy should be monitored closely in myelosuppressed, infection-prone patients.
• Live vaccines: Cytomia's immunosuppressive effect increases the risk of disseminated infection from live or live-attenuated vaccines; live vaccines should be avoided during and for a period after treatment, per specialist guidance.
• Flucytosine: Cytomia may inhibit the antifungal activity of flucytosine through competitive mechanisms; concurrent use should be monitored closely if unavoidable.

Common adverse reactions

Serious adverse reactions

Severe, potentially life-threatening myelosuppression with infection and bleeding risk; severe cerebellar and other CNS toxicity (particularly with high-dose regimens, and increased risk in renal impairment or older age); severe gastrointestinal toxicity (including bowel necrosis, reported rarely, mainly with high-dose therapy); pulmonary toxicity (including non-cardiogenic pulmonary edema, acute respiratory distress); pancreatitis; and severe hepatotoxicity — see Precautions and Warnings for details and required monitoring.

Pregnancy: Cytomia can cause fetal harm, including embryo-fetal toxicity and malformations, when administered during pregnancy, based on its mechanism of action and animal data. Cytomia should be used during pregnancy only if clearly needed and the potential benefit to the mother justifies the potential risk to the fetus; a physician must be consulted, and pregnancy should be avoided during treatment. Females of reproductive potential and males with partners of reproductive potential should use effective contraception during treatment and for a period after the last dose, as advised by the treating specialist.

Lactation: Cytomia and/or its metabolites are excreted in human milk, and serious adverse effects in a nursing infant are possible. Breastfeeding is not recommended during treatment with Cytomia and for an appropriate period after the final dose, as advised by the treating physician.

Boxed warnings

• Severe myelosuppression: Cytomia causes severe, dose-limiting bone marrow suppression (leukopenia, thrombocytopenia, anemia), which can result in serious infection and bleeding. Close monitoring of complete blood counts is required before and throughout each treatment cycle, and doses must be adjusted or withheld according to protocol for significant hematologic toxicity.
• Cytomia syndrome: A characteristic syndrome of fever, myalgia, bone pain, occasional chest pain, maculopapular rash, and conjunctivitis can occur 6–12 hours after administration. This syndrome can often be managed or prevented with corticosteroids, given under specialist guidance; therapy is usually continued if the syndrome is manageable.
• High-dose cerebellar/CNS and gastrointestinal toxicity: High-dose Cytomia regimens carry a specific risk of severe, sometimes irreversible, cerebellar and other CNS toxicity (ataxia, dysarthria, nystagmus, somnolence, seizures), and of severe gastrointestinal toxicity, including bowel necrosis. Patients on high-dose regimens require neurologic examination before each dose, and treatment must be discontinued at the first sign of neurotoxicity. Risk is increased with renal impairment, older age, and higher cumulative doses.

Other warnings and precautions

• Hepatic and renal impairment: Use with caution and reduced doses, as clearance of Cytomia/metabolites may be impaired, increasing toxicity risk (see Dosage).
• Pulmonary toxicity: Rare but serious pulmonary reactions, including non-cardiogenic pulmonary edema and acute respiratory distress, have been reported; monitor for respiratory symptoms.
• Tumor lysis syndrome: Rapid destruction of leukemic cells can cause hyperuricemia and other metabolic disturbances; appropriate prophylaxis (hydration, uric-acid-lowering therapy) and monitoring are advised, especially at treatment initiation with high tumor burden.
• Immunosuppression and infection risk: Cytomia-induced myelosuppression increases susceptibility to bacterial, fungal, and viral infections, including reactivation of latent infections; live vaccines should be avoided during treatment (see Interactions).
• Specialist administration required: Cytomia must be prescribed and administered only by, or under the direct supervision of, a physician experienced in cancer chemotherapy, in a hospital or specialist oncology/hematology setting equipped to manage severe toxicities; it is not a general-practice or outpatient self-administered medication.

Overdose with Cytomia is expected to markedly worsen its known toxicities, particularly severe, prolonged myelosuppression, and (with high-dose exposure) cerebellar/CNS and gastrointestinal toxicity. There is no specific antidote. In a suspected overdose, the infusion should be stopped immediately and the patient managed with close monitoring of blood counts and organ function, aggressive supportive care (including transfusion support, infection prophylaxis/treatment, and neurologic monitoring) as clinically indicated. Any suspected overdose requires immediate medical attention; contact emergency services or a poison control center without delay.

Store unopened Cytomia vials at room temperature (below 30°C), protected from light, unless the specific product labeling states otherwise (some reconstituted/diluted solutions may require refrigeration and have limited use periods — follow the manufacturer's instructions and institutional pharmacy protocol). Keep out of reach of children. Handle and dispose of as a hazardous/cytotoxic drug per institutional policy.

• Renal impairment: Use with caution; dose reduction is often required, particularly for high-dose regimens, due to increased risk of cerebellar/CNS and other toxicity with reduced clearance (see Dosage).
• Hepatic impairment: Use with caution and consider dose reduction, as hepatic metabolism/clearance may be affected; monitor liver function closely during treatment.
• Elderly patients: May be at increased risk of severe toxicity, including cerebellar toxicity with high-dose regimens; dose and regimen intensity should be individualized with careful monitoring.
• Pediatric patients: Used in established pediatric leukemia protocols under pediatric oncology supervision, with body-surface-area-based dosing per protocol (see Pediatric Uses).
• Patients with active infection or significant myelosuppression at baseline: Require specialist risk-benefit assessment before initiating or continuing therapy.

Duration of Cytomia therapy is protocol-specific and determined by the treating oncologist/hematologist based on the leukemia type, treatment phase (induction, consolidation, or maintenance), and the patient's response and tolerability. Induction courses are typically given over about 5–10 days per cycle, high-dose consolidation cycles are typically given over several days repeated every few weeks for a defined number of cycles, and intrathecal therapy is given at intervals defined by protocol for CNS prophylaxis or treatment. Treatment continues only as long as clinically indicated and tolerated, under ongoing specialist supervision.

Cytomia powder for injection is reconstituted according to the manufacturer's instructions, typically with sterile water for injection (bacteriostatic water for injection, if permitted by the specific product, should generally be avoided for intrathecal or high-dose use — use only diluents specified in the product's labeling). The reconstituted solution should be inspected for particulate matter and discoloration before use and further diluted as required for IV infusion per protocol; only preparations specifically intended and labeled for intrathecal use should be used intrathecally. Reconstitution and dilution must be performed by trained pharmacy/oncology personnel under appropriate hazardous-drug handling precautions, following institutional stability and storage guidance for the reconstituted/diluted solution.

Antimetabolites; Pyrimidine (cytosine) analogs; Antineoplastic agents

Cytarabine is converted intracellularly to ara-CTP, which is incorporated into DNA in place of deoxycytidine triphosphate, terminating DNA chain elongation and inhibiting DNA polymerase; this blocks DNA synthesis and repair, preferentially killing rapidly dividing cells such as leukemic blasts during the S-phase of the cell cycle.

D

Cytomia is an established component of pediatric acute leukemia treatment protocols (AML and ALL) and is used for intrathecal prophylaxis/treatment of CNS leukemia in children, under the direct supervision of a pediatric oncologist/hematologist. Dosing is determined by body surface area according to the specific validated pediatric protocol being followed; Cytomia should not be used in children outside an established leukemia treatment protocol, and close monitoring for myelosuppression and other toxicities is required, as in adults.